Hexarelin vs. Ipamorelin: A Comparative Research Guide
For in-vitro and pre-clinical laboratory research only. Not for human use.
Hexarelin and Ipamorelin are two of the most-studied growth hormone secretagogues (GHS) in the ghrelin-mimetic family. Both bind the GHS-R1a receptor and trigger pulsatile growth hormone (GH) release from the anterior pituitary, but their selectivity, potency, and downstream hormonal footprints diverge in ways that matter for study design.
Mechanism of action
Both peptides are synthetic agonists of the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by endogenous ghrelin. Activation amplifies GHRH signaling and suppresses somatostatin tone, producing a pulse of endogenous GH rather than the flat, supraphysiologic elevations associated with exogenous rhGH.
Hexarelin is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) derived from GHRP-6 with greater receptor affinity. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) engineered for high GHS-R1a selectivity with minimal off-target activity.
Receptor selectivity & off-target profile
Ipamorelin is widely characterized in the literature as the most selective GHS in its class: in published animal and early human work it raises GH without measurable increases in cortisol, prolactin, or ACTH at therapeutic-range doses (Raun et al., 1998). This clean profile is the main reason it appears in long-duration study designs.
Hexarelin is more potent on a molar basis but less selective. Studies report dose-dependent elevations in cortisol, prolactin, and ACTH, along with documented tachyphylaxis (diminishing GH response) with repeated administration over days to weeks (Imbimbo et al., 1994). It also shows independent cardioprotective signaling via the CD36 receptor — a distinct line of cardiac research interest.
Pharmacokinetics
| Parameter | Hexarelin | Ipamorelin |
|---|---|---|
| Class | Hexapeptide GHS | Pentapeptide GHS |
| GHS-R1a affinity | High | High, highly selective |
| Plasma half-life | ~55 min | ~2 hours |
| Cortisol / prolactin | Dose-dependent rise | No clinically meaningful rise |
| Tachyphylaxis | Reported with repeat dosing | Limited evidence |
| Notable off-target | CD36 (cardiac) | None established |
Research applications
Hexarelin
- GH-axis stimulation models where maximal pulse amplitude is the readout.
- Cardioprotection and ischemia-reperfusion studies leveraging CD36 signaling.
- Comparative GHS-R1a desensitization and receptor downregulation work.
Ipamorelin
- Long-duration GH-release studies where a clean endocrine profile is required.
- Models isolating GH effects from cortisol/prolactin confounders.
- Combination protocols with CJC-1295 or GHRH analogs to model pulsatile release.
Selecting between the two
The decision usually reduces to selectivity vs. potency. Choose Ipamorelin when the study design demands isolated GH-axis stimulation across a longer protocol without cortisol/prolactin confounders. Choose Hexarelin when the question is maximal acute GH response, GHS-R1a pharmacology at the upper end of activation, or non-GH CD36 signaling.
Neither peptide substitutes for the other; they answer different questions. Both should be sourced lot-traced, with a Certificate of Analysis documenting identity, mass, and ≥99% purity before any model is initiated.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552-561.
- Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. European Journal of Clinical Pharmacology, 1994;46(5):421-425.
- Bisi G, et al. Cardiovascular effects of hexarelin in humans. Journal of Endocrinological Investigation, 1999;22(5 Suppl):37-41.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 2018;6(1):45-53.